The Wnt Receptor Ryk Reduces Neuronal and Cell Survival Capacity by Repressing FOXO Activity During the Early Phases of Mutant Huntingtin Pathogenicity

PLoS Biology

Volumn 12, Issue 6, 2014, Pages

  Tourette, Cendrine ^a,b,c,d   Farina, Francesca ^a,b,c   Vazquez Manrique, Rafael P ^a,b,c,m   Orfila, Anne Marie ^a,b,c   Voisin, Jessica ^a,b,c   Hernandez, Sonia ^a,b,c   Offner, Nicolas ^a,b,c   Parker, J Alex ^a,b,c,n   Menet, Sophie ^a,b,c   Kim, Jinho ^e   Lyu, Jungmok ^f   Choi, Si Ho ^f   Cormier, Kerry ^g   Edgerly, Christina K ^e   Bordiuk, Olivia L ^e   Smith, Karen ^h   Louise, Anne ⁱ   Halford, Michael ^j   Stacker, Steven ^j   Vert, Jean Philippe ^c,k,l   Ferrante, Robert J ^e   Lu, Wange ^f   Neri, Christian ^a,b,c   more..

^a Groupe Enzymologie Moléculaire et Fonctionnelle   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c INSERM   (France)

^d HÔPITAL CHARLES FOIX   (France)

^e UNIVERSITY OF PITTSBURGH   (United States)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^g BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h GERIATRIC RESEARCH EDUCATION AND CLINICAL CENTER   (United States)

ⁱ INSTITUT PASTEUR   (France)

^j PETER MACCALLUM CANCER CENTRE   (Australia)

^k PSL RESEARCH UNIVERSITY   (France)

^l INSTITUT CURIE   (France)

^m Sensorineural Disorders   (Spain)

ⁿ CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; HUNTINGTIN; MEMBRANE RECEPTOR; POLYGLUTAMINE; PRESENILIN 1; PROTEIN RYK; TRANSCRIPTION FACTOR FOXO; UNCLASSIFIED DRUG; CAENORHABDITIS ELEGANS PROTEIN; FORKHEAD TRANSCRIPTION FACTOR; FRIZZLED PROTEIN; LIN-18 PROTEIN, C ELEGANS; PRESENILIN 1, MOUSE; PROTEIN TYROSINE KINASE; SEROTONIN TRANSPORTER; SLC6A4 PROTEIN, MOUSE;

ADULT; AGED; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CAENORHABDITIS ELEGANS; CELL NUCLEUS; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; CYTOTOXICITY; EMBRYO; FEMALE; HUMAN; HUMAN TISSUE; HUNTINGTON CHOREA; MALE; MOUSE; MUTANT; NERVE CELL; NERVE CELL NECROSIS; NEUROPROTECTION; NONHUMAN; PATHOGENESIS; PATHOGENICITY; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; TRANSCRIPTION REGULATION; ANIMAL; CELL LINE; DNA MICROARRAY; GENETICS; HUNTINGTON DISEASE; METABOLISM; MIDDLE AGED; TRANSGENIC MOUSE; WNT SIGNALING PATHWAY;

AGED; ANIMALS; CAENORHABDITIS ELEGANS; CAENORHABDITIS ELEGANS PROTEINS; CELL LINE; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; HUNTINGTON DISEASE; MALE; MICE; MICE, TRANSGENIC; MIDDLE AGED; NEURONS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PRESENILIN-1; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, WNT; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; WNT SIGNALING PATHWAY;

EID: 84903289274     PISSN: 15449173     EISSN: 15457885     Source Type: Journal    
DOI: 10.1371/journal.pbio.1001895     Document Type: Article

References (66)

1. Kikis EA, Gidalevitz T, Morimoto RI, (2010) Protein homeostasis in models of aging and age-related conformational disease. Adv Exp Med Biol 694: 138-159.
2. Eijkelenboom A, Burgering BM, (2013) FOXOs: signalling integrators for homeostasis maintenance. Nat Rev Mol Cell Biol 14: 83-97.
3. Salih DA, Brunet A, (2008) FoxO transcription factors in the maintenance of cellular homeostasis during aging. Curr Opin Cell Biol 20: 126-136.
4. Neri C, (2012) Role and therapeutic potential of the pro-longevity factor FOXO and its regulators in neurodegenerative disease. Front Pharmacol 3: 15.
5. Parmentier F, Lejeune FX, Neri C, (2013) Pathways to decoding the clinical potential of stress response FOXO-interaction networks for Huntington's disease: of gene prioritization and context dependence. Front Aging Neurosci 5: 22.
6. Gil JM, Rego AC, (2008) Mechanisms of neurodegeneration in Huntington's disease. Eur J Neurosci 27: 2803-2820.
7. Parker JA, Arango M, Abderrahmane S, Lambert E, Tourette C, et al. (2005) Resveratrol rescues mutant polyglutamine cytotoxicity in nematode and mammalian neurons. Nat Genet 37: 349-350.
8. Cohen E, Bieschke J, Perciavalle RM, Kelly JW, Dillin A, (2006) Opposing activities protect against age-onset proteotoxicity. Science 313: 1604-1610.
9. Essers MA, de Vries-Smits LM, Barker N, Polderman PE, Burgering BM, et al. (2005) Functional interaction between beta-catenin and FOXO in oxidative stress signaling. Science 308: 1181-1184.
10. Parker JA, Vazquez-Manrique RP, Tourette C, Farina F, Offner N, et al. (2012) Integration of beta-catenin, sirtuin, and FOXO signaling protects from mutant huntingtin toxicity. J Neurosci 32: 12630-12640.
11. Inestrosa NC, Arenas E, (2010) Emerging roles of Wnts in the adult nervous system. Nat Rev Neurosci 11: 77-86.
12. Caricasole A, Bakker A, Copani A, Nicoletti F, Gaviraghi G, et al. (2005) Two sides of the same coin: Wnt signaling in neurodegeneration and neuro-oncology. Biosci Rep 25: 309-327.
13. Carmichael J, Sugars KL, Bao Y, Rubinsztein DC, (2002) GSK-3beta inhibitors prevent cellular polyglutamine toxicity caused by the Huntington's disease mutation. J Biol Chem 3: 3.
14. Gines S, Ivanova E, Seong IS, Saura CA, MacDonald ME, (2003) Enhanced Akt signaling is an early pro-survival response that reflects N-methyl-D-aspartate receptor activation in Huntington's disease knock-in striatal cells. J Biol Chem 278: 50514-50522.
15. Parker JA, Connolly JB, Wellington C, Hayden M, Dausset J, et al. (2001) Expanded polyglutamines in Caenorhabditis elegans cause axonal abnormalities and severe dysfunction of PLM mechanosensory neurons without cell death. Proc Natl Acad Sci U S A 98: 13318-13323.
16. Lyu J, Yamamoto V, Lu W, (2008) Cleavage of the Wnt receptor Ryk regulates neuronal differentiation during cortical neurogenesis. Dev Cell 15: 773-780.
17. Zhong J, Kim HT, Lyu J, Yoshikawa K, Nakafuku M, et al. (2011) The Wnt receptor Ryk controls specification of GABAergic neurons versus oligodendrocytes during telencephalon development. Development 138: 409-419.
18. Keeble TR, Halford MM, Seaman C, Kee N, Macheda M, et al. (2006) The Wnt receptor Ryk is required for Wnt5a-mediated axon guidance on the contralateral side of the corpus callosum. J Neurosci 26: 5840-5848.
19. Macheda ML, Sun WW, Kugathasan K, Hogan BM, Bower NI, et al. (2012) The Wnt receptor Ryk plays a role in mammalian planar cell polarity signaling. J Biol Chem 287: 29312-29323.
20. Andre P, Wang Q, Wang N, Gao B, Schilit A, et al. (2012) The Wnt coreceptor Ryk regulates Wnt/planar cell polarity by modulating the degradation of the core planar cell polarity component Vangl2. J Biol Chem 287: 44518-44525.
21. Hollis ER 2nd, Zou Y, (2012) Reinduced Wnt signaling limits regenerative potential of sensory axons in the spinal cord following conditioning lesion. Proc Natl Acad Sci U S A 109: 14663-14668.
22. Povinelli BJ, Nemeth MJ, (2013) Wnt5a regulates hematopoietic stem cell proliferation and repopulation through the Ryk receptor. Stem Cells 32: 105-115.
23. Trettel F, Rigamonti D, Hilditch-Maguire P, Wheeler VC, Sharp AH, et al. (2000) Dominant phenotypes produced by the HD mutation in STHdh(Q111) striatal cells. Hum Mol Genet 9: 2799-2809.
24. Hickey MA, Kosmalska A, Enayati J, Cohen R, Zeitlin S, et al. (2008) Extensive early motor and non-motor behavioral deficits are followed by striatal neuronal loss in knock-in Huntington's disease mice. Neuroscience 157: 280-295.
25. Lejeune FX, Mesrob L, Parmentier F, Bicep C, Vazquez-Manrique RP, et al. (2012) Large-scale functional RNAi screen in C. elegans identifies genes that regulate the dysfunction of mutant polyglutamine neurons. BMC Genomics 13: 91.
26. Lu W, Yamamoto V, Ortega B, Baltimore D, (2004) Mammalian Ryk is a Wnt coreceptor required for stimulation of neurite outgrowth. Cell 119: 97-108.
27. Colavita A, Krishna S, Zheng H, Padgett RW, Culotti JG, (1998) Pioneer axon guidance by UNC-129, a C. elegans TGF-beta. Science 281: 706-709.
28. Russ AP, Lampel S, (2005) The druggable genome: an update. Drug Discov Today 10: 1607-1610.
29. Hodges A, Strand AD, Aragaki AK, Kuhn A, Sengstag T, et al. (2006) Regional and cellular gene expression changes in human Huntington's disease brain. Hum Mol Genet 15: 965-977.
30. Arango M, Holbert S, Zala D, Brouillet E, Pearson J, et al. (2006) CA150 expression delays striatal cell death in overexpression and knock-in conditions for mutant huntingtin neurotoxicity. J Neurosci 26: 4649-4659.
31. Berndt JD, Aoyagi A, Yang P, Anastas JN, Tang L, et al. (2011) Mindbomb 1, an E3 ubiquitin ligase, forms a complex with RYK to activate Wnt/beta-catenin signaling. J Cell Biol 194: 737-750.
32. Mojsilovic-Petrovic J, Nedelsky N, Boccitto M, Mano I, Georgiades SN, et al. (2009) FOXO3a is broadly neuroprotective in vitro and in vivo against insults implicated in motor neuron diseases. J Neurosci 29: 8236-8247.
33. Halford MM, Macheda ML, Parish CL, Takano EA, Fox S, et al. (2013) A fully human inhibitory monoclonal antibody to the Wnt receptor RYK. PLoS ONE 8: e75447 doi:75410.71371/journal.pone.0075447.
34. Cupers P, Orlans I, Craessaerts K, Annaert W, De Strooper B, (2001) The amyloid precursor protein (APP)-cytoplasmic fragment generated by gamma-secretase is rapidly degraded but distributes partially in a nuclear fraction of neurones in culture. J Neurochem 78: 1168-1178.
35. Sastre M, Steiner H, Fuchs K, Capell A, Multhaup G, et al. (2001) Presenilin-dependent gamma-secretase processing of beta-amyloid precursor protein at a site corresponding to the S3 cleavage of Notch. EMBO Rep 2: 835-841.
36. Kegel KB, Sapp E, Alexander J, Reeves P, Bleckmann D, et al. (2010) Huntingtin cleavage product A forms in neurons and is reduced by gamma-secretase inhibitors. Mol Neurodegener 5: 58.
37. Hersch SM, Rosas HR, Ferrante RJ (2004) Neuropathology and pathophysiology of Huntington's disease. Watts, RL and Koller, WC (eds), Movement disorders: neurologic principles and practice. New York: McGraw-Hill: 503-523.
38. Landis JN, Murphy CT, (2010) Integration of diverse inputs in the regulation of Caenorhabditis elegans DAF-16/FOXO. Dev Dyn 239: 1405-1412.
39. Renault VM, Rafalski VA, Morgan AA, Salih DA, Brett JO, et al. (2009) FoxO3 regulates neural stem cell homeostasis. Cell Stem Cell 5: 527-539.
40. Liu Y, Shi J, Lu CC, Wang ZB, Lyuksyutova AI, et al. (2005) Ryk-mediated Wnt repulsion regulates posterior-directed growth of corticospinal tract. Nat Neurosci 8: 1151-1159.
41. Bovolenta P, Rodriguez J, Esteve P, (2006) Frizzled/RYK mediated signalling in axon guidance. Development 133: 4399-4408.
42. Zhang Z, Hartmann H, Do VM, Abramowski D, Sturchler-Pierrat C, et al. (1998) Destabilization of beta-catenin by mutations in presenilin-1 potentiates neuronal apoptosis. Nature 395: 698-702.
43. Francis R, McGrath G, Zhang J, Ruddy DA, Sym M, et al. (2002) aph-1 and pen-2 are required for Notch pathway signaling, gamma-secretase cleavage of betaAPP, and presenilin protein accumulation. Dev Cell 3: 85-97.
44. Webb AE, Pollina EA, Vierbuchen T, Urban N, Ucar D, et al. (2013) FOXO3 shares common targets with ASCL1 genome-wide and inhibits ASCL1-dependent neurogenesis. Cell Rep 4: 477-491.
45. Li X, Li YH, Yu S, Liu Y, (2008) Upregulation of Ryk expression in rat dorsal root ganglia after peripheral nerve injury. Brain Res Bull 77: 178-184.
46. Liu Y, Wang X, Lu CC, Kerman R, Steward O, et al. (2008) Repulsive Wnt signaling inhibits axon regeneration after CNS injury. J Neurosci 28: 8376-8382.
47. Brenner S, (1974) The genetics of Caenorhabditis elegans. Genetics 77: 71-94.
48. Parker JA, Metzler M, Georgiou J, Mage M, Roder JC, et al. (2007) Huntingtin-interacting protein 1 influences worm and mouse presynaptic function and protects Caenorhabditis elegans neurons against mutant polyglutamine toxicity. J Neurosci 27: 11056-11064.
49. Vazquez-Manrique RP, Nagy AI, Legg JC, Bales OA, Ly S, et al. (2008) Phospholipase C-epsilon regulates epidermal morphogenesis in Caenorhabditis elegans. PLoS Genet 4: e1000043.
50. Duerr JS (2006) Immunohistochemistry. WormBook: 1-61.
51. Zhang Y, Ma C, Delohery T, Nasipak B, Foat BC, et al. (2002) Identification of genes expressed in C. elegans touch receptor neurons. Nature 418: 331-335.
52. Gauthier LR, Charrin BC, Borrell-Pages M, Dompierre JP, Rangone H, et al. (2004) Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 118: 127-138.
53. Miller JP, Holcomb J, Al-Ramahi I, de Haro M, Gafni J, et al. (2010) Matrix metalloproteinases are modifiers of huntingtin proteolysis and toxicity in Huntington's disease. Neuron 67: 199-212.
54. Lyu J, Wesselschmidt RL, Lu W, (2009) Cdc37 regulates Ryk signaling by stabilizing the cleaved Ryk intracellular domain. J Biol Chem 284(19): 12940-12948.
55. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, et al. (1999) Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96: 857-868.
56. Menalled LB, Sison JD, Dragatsis I, Zeitlin S, Chesselet MF, (2003) Time course of early and neuropathological anomalies in a knock-in mouse model of Huntington's disease with 140 CAG repeats. J Comp Neurol 465: 11-26.
57. Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP Jr, (1985) Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol 44: 559-577.
58. Remm M, Storm CE, Sonnhammer EL, (2001) Automatic clustering of orthologs and in-paralogs from pairwise species comparisons. J Mol Biol 314: 1041-1052.
59. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, et al. (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102: 15545-15550.
60. Murphy CT, McCarroll SA, Bargmann CI, Fraser A, Kamath RS, et al. (2003) Genes that act downstream of DAF-16 to influence the lifespan of Caenorhabditis elegans. Nature 424: 277-283.
61. McElwee J, Bubb K, Thomas JH, (2003) Transcriptional outputs of the Caenorhabditis elegans forkhead protein DAF-16. Aging Cell 2: 111-121.
62. Oh SW, Mukhopadhyay A, Dixit BL, Raha T, Green MR, et al. (2006) Identification of direct DAF-16 targets controlling longevity, metabolism and diapause by chromatin immunoprecipitation. Nat Genet 38: 251-257.
63. Kuhn A, Goldstein DR, Hodges A, Strand AD, Sengstag T, et al. (2007) Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. Hum Mol Genet 16: 1845-1861.
64. Thomas EA, Coppola G, Tang B, Kuhn A, Kim S, et al. (2011) In vivo cell-autonomous transcriptional abnormalities revealed in mice expressing mutant huntingtin in striatal but not cortical neurons. Hum Mol Genet 20: 1049-1060.
65. Borovecki F, Lovrecic L, Zhou J, Jeong H, Then F, et al. (2005) Genome-wide expression profiling of human blood reveals biomarkers for Huntington's disease. Proc Natl Acad Sci U S A 102: 11023-11028.
66. The HD iPSC Consortium, (2012) Induced pluripotent stem cells from patients with Huntington's disease show CAG-repeat-expansion-associated phenotypes. Cell Stem Cell 11: 264-278.